GeoVax to Raise Approximately 5.0 Million of Gross Proceeds in Offering Priced At-the-Market
| GOVX Stock | USD 2.64 0.16 6.45% |
Slightly above 55% of GeoVax Labs' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding GeoVax Labs suggests that some traders are interested. GeoVax Labs' investing sentiment can be driven by a variety of factors including economic data, GeoVax Labs' earnings reports, geopolitical events, and overall market trends.
GeoVax |
ATLANTA, GA, Aug. 28, 2024 -- GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and...
Read at globenewswire.com
 |
GeoVax Labs Fundamental Analysis
We analyze GeoVax Labs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeoVax Labs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeoVax Labs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
GeoVax Labs is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
GeoVax Labs Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GeoVax Labs stock to make a market-neutral strategy. Peer analysis of GeoVax Labs could also be used in its relative valuation, which is a method of valuing GeoVax Labs by comparing valuation metrics with similar companies.
Peers
GeoVax Labs Related Equities
| ZVSA | ZyVersa Therapeutics | 13.76 | ||||
| CDIO | Cardio Diagnostics | 10.34 | ||||
| ZURA | Zura Bio | 9.79 | ||||
| SONN | Sonnet Biotherapeutics | 9.37 | ||||
| ATXI | Avenue Therapeutics | 6.74 | ||||
| JAGX | Jaguar Animal | 5.50 | ||||
| QNRX | Quoin Pharmaceuticals | 4.48 | ||||
| PHIO | Phio Pharmaceuticals | 3.68 | ||||
| IBIO | Ibio | 1.24 | ||||
| OCGN | Ocugen | 1.11 | ||||
| REVB | Revelation Biosciences | 1.52 | ||||
| ATNF | 180 Life | 5.49 |
Additional Tools for GeoVax Stock Analysis
When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.